Alnylam Pharmaceuticals, Inc. (ALNY) Stock Overview
Explore Alnylam Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Alnylam Pharmaceuticals, Inc. (ALNY)
Key Financials
Key Financials
Market Cap
31.6B
P/E Ratio
37.70
EPS (TTM)
$5.55
ROE
0.94%
ALNY Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Alnylam Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ALNY on the NASDAQ shows an RSI of 42.98, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $379.65 for the NASDAQ listing.
Key metrics behind Alnylam Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of 37.70 and a market capitalization of 31.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ALNY on the NASDAQ.